e-Profile Login and ID Quick Search
Citalopram and Finasteride Recalled Due to Possible Mislabeling
Certain lots of citalopram and finasteride tablets have been voluntarily recalled by Greenstone LLC, a wholly owned subsidiary of Pfizer Inc, to the patient level due to the possibility that incorrect labels have been placed on the bottles by a third-party manufacturer. The drugs have been distributed in the US market and the recall includes citalopram 10 mg tablets (100-count bottle) with lot number FI0510058-A on the label, and finasteride 5 mg tablets (90-count bottle).
The Pfizer press release stresses that bottles labeled as citalopram Lot # FI0510058-A may contain finasteride. Women who are, or may become pregnant, should not take or handle finasteride due to the possible risk of side effects which may cause abnormalities to the external genitalia of a developing male fetus. Citalopram is contraindicated in patients taking monoamine oxidase inhibitors or pimozide. Patients who believe they may have ingested the wrong medication are advised to contact their physician as soon as possible. Bottles of either citalopram (used to treat depression) or finasteride (for the treatment of benign prostatic hyperplasia) with lot number FI050058-A should be returned to the pharmacist.
